Literature DB >> 7627635

Modulation of hemostatic balance with antithrombin III replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis.

F Carmassi1, M Morale, F De Negri, M Carrai.   

Abstract

Patients with liver failure can present both thrombotic and hemorrhagic complications because of the deficiency in coagulation factors and inhibitors (protein C and S, antithrombin III) and impairment of fibrinolytic balance. Here we report the case of a 63-year-old man with liver cirrhosis, recurrent thrombosis, and features of low-grade consumption coagulopathy, showing severe antithrombin III deficiency (about 30% of normal values). Treatment with antithrombin III (2000 U/day) and low doses of heparin (5000 U b.i.d.) was successful in modulating the coagulation system toward an antithrombotic effect. After discharge from hospital the ambulatory treatment with antithrombin III concentrates (2000 U twice a week) allowed the attainment of antithrombin III activity of about 60% and prevented the patient from recurrence of venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7627635     DOI: 10.1007/bf00270583

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  24 in total

1.  Anticoagulant action of heparin.

Authors:  P S Damus; M Hicks; R D Rosenberg
Journal:  Nature       Date:  1973-12-07       Impact factor: 49.962

Review 2.  Structure and function of protein C.

Authors:  J Stenflo
Journal:  Semin Thromb Hemost       Date:  1984-04       Impact factor: 4.180

Review 3.  Antithrombin III deficiency and thromboembolism.

Authors:  E Thaler; K Lechner
Journal:  Clin Haematol       Date:  1981-06

Review 4.  Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.

Authors:  R S Schwartz; K A Bauer; R D Rosenberg; E J Kavanaugh; D C Davies; D A Bogdanoff
Journal:  Am J Med       Date:  1989-09-11       Impact factor: 4.965

Review 5.  Congenital antithrombin III deficiency. Incidence and clinical features.

Authors:  J Hirsh; F Piovella; M Pini
Journal:  Am J Med       Date:  1989-09-11       Impact factor: 4.965

Review 6.  Clinical use of antithrombin III concentrates.

Authors:  H Vinazzer
Journal:  Vox Sang       Date:  1987       Impact factor: 2.144

7.  Detection of a new heparin-dependent inhibitor of thrombin in human plasma.

Authors:  D M Tollefsen; M K Blank
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

8.  The effect of plasma antithrombin concentration on thrombin generation and fibrin gel structure.

Authors:  G Elgue; J Sanchez; K Fatah; P Olsson; B Blombäck
Journal:  Thromb Res       Date:  1994-07-15       Impact factor: 3.944

9.  Antithrombin III patterns in disseminated intravascular coagulation.

Authors:  R L Bick; M D Bick; L F Fekete
Journal:  Am J Clin Pathol       Date:  1980-04       Impact factor: 2.493

10.  A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor thrombin and heparin.

Authors:  M W Pomerantz; W G Owen
Journal:  Biochim Biophys Acta       Date:  1978-07-21
View more
  2 in total

Review 1.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

2.  Deep Vein Thrombosis and Pulmonary Embolism in Liver Transplant Patients: Risks and Prevention.

Authors:  James Yip; David A Bruno; Charlotte Burmeister; Marwan Kazimi; Atsushi Yoshida; Marwan S Abouljoud; Gabriel T Schnickel
Journal:  Transplant Direct       Date:  2016-03-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.